ORIGINAL RESEARCH article
Front. Immunol.
Sec. Inflammation
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1492644
This article is part of the Research TopicRoad Trip from Mild to Severe Asthmatic Inflammation: The Traffic Lights of Biomarkers in Asthma Management - Volume IIView all 6 articles
Baseline Type 2 Biomarker Levels and Clinical Remission Predictors in Children with Asthma
Provisionally accepted
- 1Department of Integrative Medicine, Huashan Hospital, Fudan University, Jing'an, China
- 2Institutes of Integrative Medicine, Fudan University, Shanghai, China
- 3Department of Pediatrics, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China
- 4Children's Hospital, Fudan University, Shanghai, Shanghai Municipality, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Few studies have investigated the relationship between baseline type 2 biomarker levels and clinical features in pediatric asthma, particularly in different asthma stages, which may inform prognosis and remission.To explore the association between baseline Th2 biomarker levels and clinical manifestations in pediatric asthma, identifying predictors of clinical remission.The study included 172 children with a mean age of 6.87±3.04 years, comprising 119 asthma patients and 53 non-respiratory symptom controls. Clinical evaluations such as lung function tests, FeNO, total IgE, blood eosinophil counts, and skin tests were conducted. Serum biomarkers (TSLP, IL-4/5/13, TARC, Periostin), and IgE were measured by ELISA. Th2-high asthma (IgE >100 IU/mL and eosinophils≥140 cells/μL, n=110) was stratified into acute attack (n=48), persistent asthma (n=26), and clinical remission (n=36). Additionally, mouse models across asthma stages were established to measure TSLP levels in BALF, serum, and lung tissue, to validate its predictor value.Serum TSLP was significantly elevated in acute exacerbation and persistent asthma(P<0.01). Multivariable regression confirmed its independent association with remission (OR=1.009, P=0.023). ROC analysis indicated moderate discriminative capacity of TSLP for remission (AUC=0.59, sensitivity=39.1%, specificity=59.4%).Murine models also showed TSLP levels normalization during remission.Serum TSLP is independently associated with clinical remission in Th2-high pediatric asthma, though its standalone predictive accuracy is moderate (AUC=0.59).Integration with lung function and IgE may form a composite biomarker panel for remission evaluation. This stratification tool may guide asthma risk stratification and personalized disease management. Longitudinal studies are warranted to validate its prognostic utility.
Keywords: pediatric asthma, Th2 Biomarkers, thymic stromal lymphopoietin, Clinical asthma remission, 19]
Received: 07 Sep 2024; Accepted: 05 May 2025.
Copyright: © 2025 Dong, Chen, Li, Yang, Zhang, Zhang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jingcheng Dong, Department of Integrative Medicine, Huashan Hospital, Fudan University, Jing'an, China
Yanli Zhang, Department of Pediatrics, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China
Na Wang, Children's Hospital, Fudan University, Shanghai, 201102, Shanghai Municipality, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.